RU2011132386A - Способ повышения уровней эндогенных плазмалогенов - Google Patents
Способ повышения уровней эндогенных плазмалогенов Download PDFInfo
- Publication number
- RU2011132386A RU2011132386A RU2011132386/13A RU2011132386A RU2011132386A RU 2011132386 A RU2011132386 A RU 2011132386A RU 2011132386/13 A RU2011132386/13 A RU 2011132386/13A RU 2011132386 A RU2011132386 A RU 2011132386A RU 2011132386 A RU2011132386 A RU 2011132386A
- Authority
- RU
- Russia
- Prior art keywords
- lcpufa
- animal
- administered
- amount
- day
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 87
- 241001465754 Metazoa Species 0.000 claims abstract 81
- 235000005911 diet Nutrition 0.000 claims abstract 15
- 230000037213 diet Effects 0.000 claims abstract 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract 10
- 150000002148 esters Chemical class 0.000 claims abstract 10
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims abstract 5
- 241000282465 Canis Species 0.000 claims abstract 5
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims abstract 5
- 241000282324 Felis Species 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 5
- 150000007513 acids Chemical class 0.000 claims abstract 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract 5
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract 5
- 229940114079 arachidonic acid Drugs 0.000 claims abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract 5
- 150000002327 glycerophospholipids Chemical class 0.000 claims abstract 5
- 150000002763 monocarboxylic acids Chemical class 0.000 claims abstract 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract 5
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract 5
- 239000006014 omega-3 oil Substances 0.000 claims abstract 5
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims abstract 5
- 229940033080 omega-6 fatty acid Drugs 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000032683 aging Effects 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000036541 health Effects 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 3
- 235000012041 food component Nutrition 0.000 claims 3
- 239000005417 food ingredient Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 230000000007 visual effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000010586 diagram Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20417009P | 2009-01-02 | 2009-01-02 | |
| US61/204,170 | 2009-01-02 | ||
| PCT/US2009/006749 WO2010077358A1 (en) | 2009-01-02 | 2009-12-30 | Methods for increasing endogenous plasmalogen levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011132386A true RU2011132386A (ru) | 2013-02-10 |
Family
ID=42310073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011132386/13A RU2011132386A (ru) | 2009-01-02 | 2009-12-30 | Способ повышения уровней эндогенных плазмалогенов |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110275600A1 (https=) |
| EP (1) | EP2373161A4 (https=) |
| JP (1) | JP2012514597A (https=) |
| CN (1) | CN102271502A (https=) |
| AU (1) | AU2009333809A1 (https=) |
| CA (1) | CA2747582A1 (https=) |
| MX (1) | MX2011007188A (https=) |
| RU (1) | RU2011132386A (https=) |
| WO (1) | WO2010077358A1 (https=) |
| ZA (1) | ZA201105665B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010100060A2 (en) * | 2009-03-04 | 2010-09-10 | Nestec S.A. | Method for increasing endogenous plasmalogen levels in mammals |
| CN103314291B (zh) * | 2010-12-28 | 2016-05-11 | 藤野脑研究株式会社 | 通过血液样品判定痴呆症用的检验方法 |
| JP5934483B2 (ja) * | 2011-09-05 | 2016-06-15 | 学校法人帝京大学 | リン脂質結合型ｄｈａ増加剤 |
| JP5997887B2 (ja) * | 2011-09-05 | 2016-09-28 | 学校法人帝京大学 | 経口投与剤 |
| JP7704407B2 (ja) * | 2021-08-04 | 2025-07-08 | 株式会社 レオロジー機能食品研究所 | がん治療用組成物 |
| JP2023108631A (ja) * | 2022-01-26 | 2023-08-07 | 大道 藤本 | ドッグフード |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050027004A1 (en) * | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8052992B2 (en) * | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
| US20080033027A1 (en) * | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| US20080044487A1 (en) * | 2006-05-05 | 2008-02-21 | Natural Asa | Anti-inflammatory properties of marine lipid compositions |
| JP5220842B2 (ja) * | 2007-04-13 | 2013-06-26 | フェノメノーム ディスカバリーズ インク | プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法 |
-
2009
- 2009-12-30 RU RU2011132386/13A patent/RU2011132386A/ru not_active Application Discontinuation
- 2009-12-30 WO PCT/US2009/006749 patent/WO2010077358A1/en not_active Ceased
- 2009-12-30 US US13/138,066 patent/US20110275600A1/en not_active Abandoned
- 2009-12-30 CN CN2009801536386A patent/CN102271502A/zh active Pending
- 2009-12-30 CA CA2747582A patent/CA2747582A1/en not_active Abandoned
- 2009-12-30 JP JP2011544414A patent/JP2012514597A/ja active Pending
- 2009-12-30 AU AU2009333809A patent/AU2009333809A1/en not_active Abandoned
- 2009-12-30 EP EP09836535A patent/EP2373161A4/en not_active Withdrawn
- 2009-12-30 MX MX2011007188A patent/MX2011007188A/es not_active Application Discontinuation
-
2011
- 2011-08-01 ZA ZA2011/05665A patent/ZA201105665B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010077358A1 (en) | 2010-07-08 |
| CN102271502A (zh) | 2011-12-07 |
| US20110275600A1 (en) | 2011-11-10 |
| MX2011007188A (es) | 2011-09-01 |
| EP2373161A4 (en) | 2012-05-30 |
| EP2373161A1 (en) | 2011-10-12 |
| ZA201105665B (en) | 2013-01-30 |
| JP2012514597A (ja) | 2012-06-28 |
| AU2009333809A1 (en) | 2011-07-14 |
| CA2747582A1 (en) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Drouin et al. | The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family | |
| Cederholm | Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia or Alzheimer's disease in older adults–any news? | |
| Basak et al. | Maternal supply of both arachidonic and docosahexaenoic acids is required for optimal neurodevelopment | |
| AU2016202685B2 (en) | Compositions and methods for enhancing cognitive function | |
| Simopoulos | Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk | |
| RU2011132386A (ru) | Способ повышения уровней эндогенных плазмалогенов | |
| EP3310349B1 (en) | Compositions and methods for enhancing neurogenesis in animals | |
| Stephenson et al. | Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition improve cognition: a randomized, triple-blinded, controlled clinical trial | |
| RU2010132637A (ru) | Композиции, включающие ненасыщенные жирные кислоты и соединения, высбождающие оксид азота, и их применение для усиления когнитивной функции и связанных с ней функцией | |
| Georgel et al. | Where epigenetics meets food intake: their interaction in the development/severity of gout and therapeutic perspectives | |
| Brenna et al. | Balancing omega-6 and omega-3 fatty acids in ready-to-use therapeutic foods (RUTF) | |
| Taha et al. | Seizure resistance in fat‐1 transgenic mice endogenously synthesizing high levels of omega‐3 polyunsaturated fatty acids | |
| Shaforostova et al. | Neuroprotective effect of mildronate and L-carnitine on the cognitive parameters of aged mice and mice with LPS-induced inflammation | |
| Arghavani et al. | Association between circulating fatty acids and blood pressure: a review | |
| Walczak et al. | Effect of creatine supplementation on cognitive function and mood | |
| RU2013131098A (ru) | Способы и композиции, предназначенные для улучшения сна у животных | |
| Miller et al. | Alterations in levels and ratios of n–3 and n–6 polyunsaturated fatty acids in the Temporal cortex and liver of Vervet monkeys from birth to early adulthood | |
| AU2015358958A1 (en) | Compositions and methods comprising medium chain triglycerides for treatment of epilepsy | |
| Vendramini et al. | Exploring the efficacy and optimal dosages of omega-3 supplementation for companion animals | |
| Vaezi | Efficacy and Biomedical Roles of Unsaturated Fatty Acids as Bioactive Food Components | |
| Gillingham | The metabolic fate of alpha linolenic acid (ALA) | |
| Marcos et al. | Cognition and Omega-3 Fatty Acids-A Narrative Review of the Literature | |
| Bailey | Current choices in omega 3 supplementation | |
| Silldorff et al. | Reducing cardiovascular risk-are omega 3 fatty acids the solution? | |
| Duttaroy | Maternal DHA Impact on Child Neurodevelopment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20150209 |